We demonstrate an aberrant ramification pattern of the renal and testicular vessels. On both sides, the anterior and posterior renal veins emerged from the renal. On the right side, the anterior renal vein collected the right testicular vein and drained into the inferior vena cava, while the posterior one directly drained into the inferior vena cava. Two retrocaval testicular arteries originated from the aorta. On the left side, the perinephric vein drained from the abdominal wall and adrenal gland and joined the anterior renal vein. The anterior renal vein also collected the testicular, suprarenal, and inferior phrenic veins. The posterior one received the other testicular vein and the first three lumbar veins. These renal veins converged, passed anteriorly to the aorta, and drained into the inferior vena cava. Knowledge of the varied anatomy of these vessels will contribute to safe surgical approach to the kidneys.

We demonstrate an aberrant ramification pattern of the renal and testicular vessels. On both sides, the anterior and posterior renal veins emerged from the renal. On the right side, the anterior renal vein collected the right testicular vein and drained into the inferior vena cava, while the posterior one directly drained into the inferior vena cava. Two retrocaval testicular arteries originated from the aorta. On the left side, the perinephric vein drained from the abdominal wall and adrenal gland and joined the anterior renal vein. The anterior renal vein also collected the testicular, suprarenal, and inferior phrenic veins. The posterior one received the other testicular vein and the first three lumbar veins. These renal veins converged, passed anteriorly to the aorta, and drained into the inferior vena cava. Knowledge of the varied anatomy of these vessels will contribute to safe surgical approach to the kidneys.

We demonstrate an aberrant ramification pattern of the renal and testicular vessels. On both sides, the anterior and posterior renal veins emerged from the renal. On the right side, the anterior renal vein collected the right testicular vein and drained into the inferior vena cava, while the posterior one directly drained into the inferior vena cava. Two retrocaval testicular arteries originated from the aorta. On the left side, the perinephric vein drained from the abdominal wall and adrenal gland and joined the anterior renal vein. The anterior renal vein also collected the testicular, suprarenal, and inferior phrenic veins. The posterior one received the other testicular vein and the first three lumbar veins. These renal veins converged, passed anteriorly to the aorta, and drained into the inferior vena cava. Knowledge of the varied anatomy of these vessels will contribute to safe surgical approach to the kidneys.

We demonstrate an aberrant ramification pattern of the renal and testicular vessels. On both sides, the anterior and posterior renal veins emerged from the renal. On the right side, the anterior renal vein collected the right testicular vein and drained into the inferior vena cava, while the posterior one directly drained into the inferior vena cava. Two retrocaval testicular arteries originated from the aorta. On the left side, the perinephric vein drained from the abdominal wall and adrenal gland and joined the anterior renal vein. The anterior renal vein also collected the testicular, suprarenal, and inferior phrenic veins. The posterior one received the other testicular vein and the first three lumbar veins. These renal veins converged, passed anteriorly to the aorta, and drained into the inferior vena cava. Knowledge of the varied anatomy of these vessels will contribute to safe surgical approach to the kidneys.

We demonstrate an aberrant ramification pattern of the renal and testicular vessels. On both sides, the anterior and posterior renal veins emerged from the renal. On the right side, the anterior renal vein collected the right testicular vein and drained into the inferior vena cava, while the posterior one directly drained into the inferior vena cava. Two retrocaval testicular arteries originated from the aorta. On the left side, the perinephric vein drained from the abdominal wall and adrenal gland and joined the anterior renal vein. The anterior renal vein also collected the testicular, suprarenal, and inferior phrenic veins. The posterior one received the other testicular vein and the first three lumbar veins. These renal veins converged, passed anteriorly to the aorta, and drained into the inferior vena cava. Knowledge of the varied anatomy of these vessels will contribute to safe surgical approach to the kidneys.

Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In the future, more emphasis should be placed on the quantification of liver fat. Traditionally, fatty liver has been assessed by histological evaluation, which requires an invasive examination; however, technological innovations have made it possible to evaluate fatty liver by non-invasive imaging methods, such as ultrasonography, computed tomography, and magnetic resonance imaging. In addition, quantitative as well as qualitative measurements for the detection of fatty liver have become available. In this review, we summarize the currently used qualitative evaluations of fatty liver and discuss quantitative evaluations that are expected to further develop in the future.

The identification code of a drug is defined as “a code for identifying tablets, etc.” and is described in the “Composition/Properties” section of the package insert. We investigated whether the Pharmaceuticals and Medical Devices Agency (PMDA) website, which allows users to search package insert information, can be used for drug identification using identification codes in 2019 before the new package insert guidelines were implemented, and in 2022, during the revision period. Approximately 30% of the investigated high-risk drugs were unidentifiable in both years. The most common reason was that images were used to register identification codes on the PMDA website, and character strings were not searchable. We then conducted a questionnaire survey of pharmaceutical companies, and only approximately half of the respondents opined that it would be preferable if the registration format for identification codes was established within the pharmaceutical industry. However, hospital pharmacists urged for more simplified identification of drugs on the PMDA website.

A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domains (HR1 and HR2) of SARS-CoV-2 spike (S) were used to design the peptides. A total of twelve peptides were generated, comprising a short or truncated 24-mer (peptide #1), a long 36-mer peptide (peptide #2), and ten peptide #2 analogs. In contrast to SARS-CoV, SARS-CoV-2 S-mediated cell-cell fusion cannot be inhibited with a minimal length, 24-mer peptide. Peptide #2 demonstrated potent inhibition of SARS-CoV-2 S-mediated cell-cell fusion at 1 µM concentration. Three peptide #2 analogs showed IC50 values in the low micromolar range (4.7-9.8 µM). Peptide #2 inhibited the SARSCoV-2 pseudovirus assay at IC50=1.49 µM. Given their potent inhibition of viral activity and safety and lack of cytotoxicity, these peptides provide an attractive avenue for the development of new prophylactic and therapeutic agents against SARS-CoV-2.

A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domains (HR1 and HR2) of SARS-CoV-2 spike (S) were used to design the peptides. A total of twelve peptides were generated, comprising a short or truncated 24-mer (peptide #1), a long 36-mer peptide (peptide #2), and ten peptide #2 analogs. In contrast to SARS-CoV, SARS-CoV-2 S-mediated cell-cell fusion cannot be inhibited with a minimal length, 24-mer peptide. Peptide #2 demonstrated potent inhibition of SARS-CoV-2 S-mediated cell-cell fusion at 1 µM concentration. Three peptide #2 analogs showed IC50 values in the low micromolar range (4.7-9.8 µM). Peptide #2 inhibited the SARSCoV-2 pseudovirus assay at IC50=1.49 µM. Given their potent inhibition of viral activity and safety and lack of cytotoxicity, these peptides provide an attractive avenue for the development of new prophylactic and therapeutic agents against SARS-CoV-2.